 | This lead contains promotional content. Please help improve it by removing promotional language and inappropriate external links, and by adding encyclopedic text written from a neutral point of view. (August 2021) (Learn how and when to remove this message) |
 | |
| Formerly | Indegene Lifesystems Private Limited (1998–2016) Indegene Private Limited (2016–2022) |
|---|---|
| Company type | Public |
| Traded as | |
| Industry | Pharmaceutical consultancy |
| Founded | 1998; 26 years ago (1998) |
| Founders | Rajesh Nair Manish Gupta Sanjay Parikh Anand Kiran Gaurav Kapoor |
| Headquarters | Bangalore, India |
| Area served | Worldwide |
| Key people | Manish Gupta (CEO) |
| Revenue |  ₹2,589 crore (US$310 million) (FY24) |
| Operating income | ₹584 crore (US$70 million) (FY24) |
| Net income | ₹336 crore (US$40 million) (FY24) |
| Owners |
|
| Number of employees | 5,081 (March 2024) |
| Website | www |
Indegene Limited is an Indian company that provides research and commercialization services to biopharmaceutical and healthcare enterprises. Based in Bangalore, the company provides consulting in pharmaceutical marketing, clinical trials, pharmacovigilance, medical and regulatory affairs, and health informatics.
History
Indegene was founded in 1998 by Dr. Rajesh Nair, Manish Gupta, Gaurav Kapoor, Dr.Sanjay Parikh and Anand Kiran. Indegene's first acquisition was Medsn, a company that provided medical education. Medsn continued to operate under the same name in the United States. In 2008, Medsn officially became Indegene Pharmaceutical Solutions in the United States. In 2006, Indegene acquired MedCases, a continuing medical education company based in the United States.
In 2009, Indegene signed a master service agreement with six pharmaceutical companies. The following year, Indegene acquired Canada-based Aptilon, a multichannel marketing firm, for $4 million. The company subsequently acquired Atlanta-based Total Therapeutic Management in 2014.
In September 2019, Indegene acquired London-based consulting company, DT Associates, for $10 million.
In February 2021, the Carlyle Group and Brighton Park Capital invested $200 million in Indegene. In August 2021, Indegene acquired Medical Marketing Economics (MME), an American market access and pricing strategy company, for $10 million.
Indegene went public in May 2024 with an initial public offering, raising ₹1,842 crore (US$220 million). It listed on the BSE and the NSE.
Operations
Indegene has offices in India, the United States, the European Union, and Asia-Pacific.
In 2011 and 2012, The Economic Times named Indegene one of the best companies to work for in the Professional Services industry.
References
- "Indegene ends 26% higher on listing day". 13 May 2024.
- "Indegene on the prowl for global acquisitions". The Hindu Businessline. 12 August 2020. Retrieved 8 January 2023.
- ^ "Fact Sheet – Q4 FY2024" (PDF). Indegene. Retrieved 30 May 2024.
- "Carlyle Group sells 4.3% in Indegene for ₹636 cr". The Economic Times. 3 December 2024. Retrieved 4 December 2024.
- Das, Avik (2 September 2015). "Flipkart, Practo CEOs get top rating from staff". The Economic Times. Archived from the original on 8 September 2015. Retrieved 2 October 2015.
- ^ Singh, Seema (7 May 2009). "Cutting pharma costs by intelligent marketing". Mint. Retrieved 2 October 2015.
- ^ Unnikrishnan, CH (8 November 2006). "Indegene buys US firm". Business Standard. Retrieved 2 October 2015.
- Murayama, Keiichi (19 February 2015). "India's tech muscle has the world's attention". The Nikkei. Retrieved 2 October 2015.
- "Indegene files papers with Sebi; eyes ₹3,200 crore via IPO". mint. 15 December 2022. Retrieved 8 January 2023.
- Amirapu, Deepika (9 March 2012). "Indegene eyes US call centre buy for $10–15 million". The Economic Times. Archived from the original on 19 November 2015. Retrieved 2 October 2015.
- D'Silva, Jeetha (17 September 2005). "Indegene acquires US medical education co". The Economic Times. Archived from the original on 16 October 2015. Retrieved 2 October 2015.
- ^ "Indegene acquires MedCases, LLC". NFV Zone. 30 November 2006. Retrieved 2 October 2015.
- "Indegene highlights benefits of patient adherence programs for pharma cos". PharmaBiz. 3 June 2011. Retrieved 2 October 2015.
- Mukherjee, Rupali (7 November 2012). "Indegene to acquire Canada-based company for $4 million". Times of India. Retrieved 2 October 2015.
- Craig, Tara (9 January 2014). "Indegene acquires Total Therapeutic Management". PMLive.com. Retrieved 2 October 2015.
- Balakrishnan, Reghu (3 September 2019). "Healthcare tech firm Indegene acquires DT Associates". The Economic Times. Retrieved 28 April 2024.
- Madhurima, Nandy (3 February 2021). "Indegene to raise $200 mn from Carlyle, Brighton Park". LiveMint. Retrieved 20 August 2021.
- Baruah, Ayushman (30 August 2021). "Indegene acquires US-based Medical Marketing Economics for $10 mn". Mint. Retrieved 28 April 2024.
- Narayanan, KS Badri (6 May 2024). "Indegene IPO opens today in ₹430-452 price band". BusinessLine. Retrieved 6 May 2024.
- "PE firms Carlyle, Nadathur Fareast, Brighton Park Capital-backed Indegene IPO to open on May 6". Moneycontrol. Retrieved 28 April 2024.
- Vijay, Nandita (7 November 2012). "Indegene plans next phase of growth through acquisition in US, EU markets". PharmaBiz. Retrieved 2 October 2015.
- "Best companies to work for 2012: Companies that came up trumps across various sectors". The Economic Times. 16 July 2012. Archived from the original on 11 April 2013. Retrieved 2 October 2015.